Back to search

Article

Pre-infusion plasma proteomics identifies an endothelial–immune priming signature predictive of severe cytokine release syndrome and neurotoxicity following CAR T-cell therapy in relapsed/refractory lymphoma

2026-03-31

Abstract excerpt

<h4>Background</h4> Severe cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) remain frequent, life-threatening complications of CD19 chimeric antigen receptor (CAR) T-cell therapy and constrain its safety, scalability, and outpatient adoption. Existing predictive models lack sufficient external validation for routine clinical use, and pre-infusion biomarkers that c...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
4c8004e9-7fff-5ce6-b96d-f3d6199d2437
DOI
10.64898/2026.03.29.26349664
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Pre-infusion plasma proteomics identifies an endothelial–immune priming signature predictive of severe cytokine release syndrome and neurotoxicity following CAR T-cell therapy in relapsed/refractory lymphomaDOI 10.64898/2026.03.29.26349664
Select a neighboring publication to make it the new centre.